- Conditions
- Colorectal Cancer
- Interventions
- bortezomib, fluorouracil, radiation therapy
- Drug · Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors
- Interventions
- Oral repotrectinib (TPX-0005)
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 49
- States / cities
- Duarte, California • Glendale, California • La Jolla, California + 36 more
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
- Interventions
- SBT6050, trastuzumab deruxtecan, tucatinib, trastuzumab, capecitabine
- Drug
- Lead sponsor
- Silverback Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Duct Cell Adenocarcinoma of the Pancreas, Intestinal Adenocarcinoma of the Stomach, Localized Unresectable Adult Primary Liver Cancer, Metastatic Carcinoma of Unknown Primary, Metastatic Extrahepatic Bile Duct Cancer, Mixed Adenocarcinoma of the Stomach, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Newly Diagnosed Carcinoma of Unknown Primary, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage III Pancreatic Cancer, Stage IIIA Colon Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Gastric Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Gastric Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Gastric Cancer, Stage IIIC Rectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colon Cancer, Stage IVA Gallbladder Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Gallbladder Cancer, Stage IVB Rectal Cancer, Unresectable Extrahepatic Bile Duct Cancer
- Interventions
- oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Evanston, Illinois
- Conditions
- Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC, Metastatic Colon Cancer, Colon Cancer, Advanced Colorectal Cancer
- Interventions
- CBI-1214
- Biological
- Lead sponsor
- Cartography Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 4 more
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
- Interventions
- IDE-161, Pembrolizumab
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
- Conditions
- Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
- Interventions
- ALT-836 in combination with gemcitabine
- Biological
- Lead sponsor
- Altor BioScience
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Iowa City, Iowa • Rochester, New York + 1 more
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Interventions
- tisotumab vedotin, pembrolizumab, carboplatin, cisplatin
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 124
- States / cities
- Encinitas, California • La Jolla, California • Sacramento, California + 57 more
- Conditions
- Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma, RAS Family Gene Mutation, Stage III Colon Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Trametinib, Trifluridine and Tipiracil Hydrochloride
- Other · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 8
- States / cities
- Corona, California • Duarte, California • Lancaster, California + 5 more
- Conditions
- Solid Tumor, Adult
- Interventions
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
- Combination Product
- Lead sponsor
- Trishula Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced, Lymphoma, Metastatic Cancer, Non-Small Cell Lung Cancer, Sarcoma, Solid Tumors
- Interventions
- Modified FOLFOX6, Conatumumab, Ganitumab, Bevacizumab
- Drug · Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 10
- States / cities
- Duarte, California • La Jolla, California • Denver, Colorado + 7 more
- Conditions
- Colorectal Cancer
- Interventions
- BMS-247550
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 15
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- nab-sirolimus
- Drug
- Lead sponsor
- Aadi Bioscience, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • New Orleans, Louisiana • Las Vegas, Nevada + 3 more
- Conditions
- Advanced Colorectal Cancer
- Interventions
- DS-8201a 5.4 mg/kg Q3W, DS-8201a 6.4 mg/kg Q3W
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Interventions
- AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 17
- States / cities
- Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
- Conditions
- Advanced Solid Tumors
- Interventions
- OSI-930
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Boston, Massachusetts
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
- Interventions
- IDOV-Immune (oncolytic vaccinia virus)
- Biological
- Lead sponsor
- ViroMissile, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Houston, Texas • San Antonio, Texas
- Conditions
- BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Cetuximab, Irinotecan, Panitumumab, Regorafenib
- Biological · Drug
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Cetuximab, Irinotecan Hydrochloride, Pharmacodynamic Study, Utomilumab
- Biological · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
- Interventions
- PF-07062119, Anti-PD1, Anti-VEGF
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Santa Monica, California + 6 more
- Conditions
- Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma, Duodenal Cancer, Colorectal Cancer, Small Bowel Cancer, Metastatic Cancers
- Interventions
- KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Cetuximab, BAY 43-9006
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Epithelial Ovarian Cancer, BRCA2 Mutation, ER+ Breast Cancer, Castrate Resistant Prostate Cancer, BRCA1 Mutation, BRCA Mutation, Endometrial Cancer, Colorectal Cancer, Gastric Cancer
- Interventions
- ETX-19477
- Drug
- Lead sponsor
- 858 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 10 more
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
- Interventions
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more